Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

Business Leaders

HomeAll NewsMost read newsBusiness Leaders Biography 
Portrait de Andrew Young
Age : 47
Public asset : 2,697,059 USD
Country of residence : Unknown
Linked companies : Capital One Financial Corporation

Biography of Andrew Young 
Andrew M. Young is Chief Financial Officer of Capital One Financial Corp.


Current positions of Andrew Young 
Holdings of Andrew Young 
Andrew Young : Personal Network 
Most Read News 
05/30Stellantis will need one or two additional U.S. battery plants - Tavares
RE
05/29Republicans speak out against US debt-ceiling deal, in sign of rocky road ahead
RE
06/05Exclusive-Crypto giant Binance controlled 'independent' US affiliate's bankáaccounts
RE
06/02JPMorgan's Dimon visits Taiwan to meet staff, clients -source
RE
06/06Microsoft's Smith meets UK finance minister after Activision block
RE
11:35aWEEKLY PREVIEW: Dates until June 20, 2023
DP
06/06Qantas CEO Alan Joyce sells $11 mln in shares ahead of retirement
RE
05/30Elon Musk kicks off China visit, Tesla expansion in focus
RE
06/05Exclusive-Musk's Neuralink valued at about $5 billion despite long road to market
RE
06/01Stellantis does not need Italy among its shareholders, Chairman Elkann says
RE
More news


© 2023 People and Ownership :   
Andrew Young : Connections 


Latest news about Andrew Young 
04/27Transcript : Capital One Financial Corporation, Q1 2023 Earnings Call, Apr 27, 2023
CI
01/24Transcript : Capital One Financial Corporation, Q4 2022 Earnings Call, Jan 24, 2023
CI
2022Certain Common Shares of Optimus Group Company Limited are subject to a Lock-Up Agreement Ending on 21-DEC-2022.
CI
2022Transcript : Capital One Financial Corporation, Q3 2022 Earnings Call, Oct 27, 2022
CI
2022Arcutis Biotherapeutics, Inc. completed the acquisition of Ducentis BioTherapeutics Limited from LifeArc Seed fund managed by LifeArc, Endowment Arm for approximately $430 million.
CI
2022Arcutis Biotherapeutics, Inc. entered into an agreement to acquire Ducentis BioTherapeutics Limited for approximately $430 million.
CI
2022Transcript : Capital One Financial Corporation, Q2 2022 Earnings Call, Jul 21, 2022
CI
More news

Stock markets for all
100% Free Registration
fermer